IP Verse

Capsule Pharmaceutical Dosage Form Comprising A Suspension Formulation Of An Indolinone Derivative

Patent No. EP2299987 (titled "Capsule Pharmaceutical Dosage Form Comprising A Suspension Formulation Of An Indolinone Derivative") was filed by Boehringer Ingelheim on Jun 4, 2009. The application was issued on Feb 21, 2018.

Patent Summary

Active substance 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate. The active substance includes a lipid suspension containing a viscous suspension of 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate, which is based on a lipid suspension formulation.

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GALENICUM HEALTH SLUNov 21, 2018GALENICUM HEALTH SLU
GENERICS UKNov 21, 2018TER MEER STEINMEISTER & PARTNER
TEVA PHARMACEUTICALSNov 21, 2018KRAUS & LEDERER PARTGMBB
ZENTIVA GROUPNov 21, 2018GREINER

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2299987

BOEHRINGER INGELHEIM
Application Number
EP09757593A
Filing Date
Jun 4, 2009
Status
Granted And Under Opposition
Jan 19, 2018
Publication Date
Feb 21, 2018
External Links
Slate, Register , Google Patents